← Back to headlines
Annexon Outlines Q4 BLA Filing for Tanruprubart
Annexon has detailed its plans for a Q4 Biologics License Application (BLA) filing for tanruprubart, additionally incorporating a month 24 dual primary endpoint into its ARCHER II study.
12 Aug, 18:08 — 12 Aug, 18:08
Sources
Showing 1 of 1 sources
Related Stories
HDFC Bank CEO Sashidhar Jagdishan to Step Down in October
1h ago
FSSAI Bans Everest and Laljee Godhoo From Selling Substandard Hing Powder
2h ago
UAE Central Bank Launches Probe Into Banque Misr Over US Money Laundering Warnings
3h ago
S&P, Nasdaq end lower after Fed Chair Warsh reaffirms inflation fight - Reuters
3h ago